 <h1>Nelfinavir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to nelfinavir: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, nelfinavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking nelfinavir:</p><p>
<i>Less common</i>
</p><ul>
<li>Confusion</li>
<li>dehydration</li>
<li>dry or itchy skin</li>
<li>fruity mouth odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>nausea</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>cough</li>
<li>dark urine</li>
<li>difficulty with breathing</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>fever</li>
<li>headache</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>muscle tremors</li>
<li>noisy breathing</li>
<li>rapid, deep breathing</li>
<li>recurrent fainting</li>
<li>restlessness</li>
<li>skin rash</li>
<li>stomach cramps</li>
<li>tightness in the chest</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of nelfinavir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Intestinal gas</li>
<li>redistribution or accumulation of body fat</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to nelfinavir: oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>Most side effects were of mild severity.  The most common side effect was diarrhea, which was usually of mild to moderate severity.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 20%)</p>
<p><b>Common</b> (1% to 10%): Nausea, flatulence</p>
<p><b>Frequency not reported</b>: Abdominal pain, dyspepsia, epigastric pain, gastrointestinal bleeding, increased amylase, mouth ulceration, pancreatitis, vomiting<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increased bleeding (including spontaneous skin hematomas and hemarthrosis) in patients with hemophilia type A and B has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased lymphocytes, decreased neutrophils, decreased hemoglobin</p>
<p><b>Frequency not reported</b>: Anemia, leukopenia, thrombocytopenia</p>
<p></p>
<p>HIV protease inhibitor therapy:</p>
<p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT</p>
<p><b>Frequency not reported</b>: Elevated GGT, abnormal liver function tests, hepatitis</p>
<p><b>Postmarketing reports</b>: Jaundice, bilirubinemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Elevated creatine kinase</p>
<p><b>Frequency not reported</b>: Arthralgia, arthritis, back pain, cramps, increased creatine phosphokinase, myalgia, myasthenia, myopathy<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Frequency not reported</b>: Dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruritus, sweating, urticaria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Dizziness, headache, hyperkinesia, migraine, paresthesia, seizures, somnolence<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Accidental injury, asthenia, fever, malaise, pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Dyspnea, pharyngitis, rhinitis, sinusitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: QTc prolongation, torsades de pointes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Anorexia, increased alkaline phosphatase, increased LDH, hyperlipidemia, hyperuricemia, hyperglycemia, hypoglycemia, dehydration, redistribution/accumulation of body fat</p>
<p><b>Postmarketing reports</b>: Metabolic acidosis</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")</p>
<p></p>
<p>HIV protease inhibitor therapy:</p>
<p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, ketoacidosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety, depression, emotional lability, insomnia, sleep disorder, suicidal ideation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reaction</p>
<p><b>Postmarketing reports</b>: Hypersensitivity reactions (including bronchospasm, moderate to severe rash, fever, edema)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Kidney calculus<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Sexual dysfunction, urine abnormality<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)</p><h3>Ocular</h3><p><b>Frequency not reported</b>: Acute iritis, eye disorder<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA. </p><p id="ref_2">2. AIDSinfo. NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2015 Mar 5]):</p><p id="ref_3">3. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2015 Apr 8]):</p><p id="ref_4">4. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_5">5. Gathe J, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman  S "A randomized phase II study of VIRACEPT, a novel HIV proteas inhibitor, used in combination with stavudine (d4T) vs. stavudin (d4T) alone." Int Conf AIDS 11 (1996): 25(ab.no.mo.b.413)</p><p id="ref_6">6. Damle B,  Hewlett D Jr,  Hsyu PH,  Becker M,  Petersen A "Pharmacokinetics of nelfinavir in subjects with hepatic impairment." J Clin Pharmacol 46 (2006): 1241-9</p><p id="ref_7">7. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8</p><p id="ref_8">8. Aarnoutse RE,  Droste JA,  Van Oosterhout JJ, et al. "Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers." Br J Clin Pharmacol 55 (2003): 115-125</p><p id="ref_9">9. Ghosn J,  Lamotte C,  Ait-Mohand H, et al. "Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients." AIDS 17 (2003): 209-14</p><p id="ref_10">10. Guest JL,  Ruffin C,  Tschampa JM,  DeSilva KE,  Rimland D "Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir." Pharmacotherapy 24 (2004): 727-35</p><p id="ref_11">11. Perry CM,  Frampton JE,  McCormack PL,  Siddiqui MA,  Cvetkovic RS "Nelfinavir: A Review of its Use in the Management of HIV Infection." Drugs 65 (2005): 2209-44</p><p id="ref_12">12. Heeswijk RP,  Khaliq Y,  Gallicano KD, et al. "The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum." Clin Pharmacol Ther 76 (2004): 588-97</p><p id="ref_13">13. Moyle GJ, Youle M, Higgs C, Monaghan J,  Peterkin J, Chapman S, Nelson M "Extended follow-up of safety and activity of agouron's HIV proteinas inhibitor ag1343 (Viracept) in virological responders from the UK phase I/II dose finding study." Int Conf AIDS 11 (1996): 18(ab.no.mo.b.173)</p><p id="ref_14">14. Flanigan TP, Ramratnam B, Graeber C, Hellinger J, Smith D, Wheeler D, Hawley P, Heathchiozzi M, Ward DJ, Brummitt C, Turner J "Prospective trial of paromomycin for cryptosporidiosis in AIDS." Am J Med 100 (1996): 370-2</p><p id="ref_15">15. Hsyu PH,  Schultz-Smith MD,  Lillibridge JH,  Lewis RH,  Kerr BM "Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin." Antimicrob Agents Chemother 45 (2001): 3445-50</p><p id="ref_16">16. Timmermans S,  Tempelman C,  Godfried MH, et al. "Nelfinavir and nevirapine side effects during pregnancy." AIDS 19 (2005): 795-799</p><p id="ref_17">17. Regazzi M,  Maserati R,  Villani P, et al. "Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects." Antimicrob Agents Chemother 49 (2005): 643-9</p><p id="ref_18">18. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_19">19. Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000): s135-42</p><p id="ref_20">20. Gathe JC Jr,  Ive P,  Wood R, et al. "SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients." AIDS 18 (2004): 1529-1537</p><p id="ref_21">21. Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A "Nelfinavir plasma levels under twice-daily and three-times-daily regimens: High interpatient and low intrapatient variability." Ther Drug Monit 23 (2001): 394-8</p><p id="ref_22">22. Puro V,  Soldani F,  De Carli G,  Lazarevic Z,  Mattioli F,  Ippolito G "Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis." AIDS 17 (2003): 1988-90</p><p id="ref_23">23. Abraham PE,  Sorensen SJ,  Baker WH,  Cushing HE "Nelfinavir desensitization." Ann Pharmacother 35 (2001): 553-6</p><p id="ref_24">24. Manfredi R, Calza L, Chiodo F "Gynecomastia associated with highly antiretroviral therapy." Ann Pharmacother 35 (2001): 438-9</p><p id="ref_25">25. Martinez E, Mocroft A, GarciaViejo MA, PerezCuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell "Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study." Lancet 357 (2001): 592-8</p><p id="ref_26">26. Dube MP,  Parker RA,  Tebas P, et al. "Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides." AIDS 19 (2005): 1807-1818</p><p id="ref_27">27. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_28">28. Fantoni M,  Del Borgo C,  Autore C "Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy." AIDS 17 Suppl 1 (2003): S162-9</p><p id="ref_29">29. Fisac C,  Virgili N,  Ferrer E, et al. "A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study." J Clin Endocrinol Metab 88 (2003): 5186-92</p><p id="ref_30">30. Engeler DS,  John H,  Rentsch KM,  Ruef C,  Oertle D,  Suter S "Nelfinavir urinary stones." J Urol 167 (2002): 1384-5</p><p id="ref_31">31. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p></div>
<div class="more-resources" id="moreResources">
<h2>More about nelfinavir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: protease inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nelfinavir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Viracept</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to nelfinavir: oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>Most side effects were of mild severity.  The most common side effect was diarrhea, which was usually of mild to moderate severity.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 20%)</p><p><b>Common</b> (1% to 10%): Nausea, flatulence</p><p><b>Frequency not reported</b>: Abdominal pain, dyspepsia, epigastric pain, gastrointestinal bleeding, increased amylase, mouth ulceration, pancreatitis, vomiting<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increased bleeding (including spontaneous skin hematomas and hemarthrosis) in patients with hemophilia type A and B has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased lymphocytes, decreased neutrophils, decreased hemoglobin</p><p><b>Frequency not reported</b>: Anemia, leukopenia, thrombocytopenia</p><p></p><p>HIV protease inhibitor therapy:</p><p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT</p><p><b>Frequency not reported</b>: Elevated GGT, abnormal liver function tests, hepatitis</p><p><b>Postmarketing reports</b>: Jaundice, bilirubinemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Elevated creatine kinase</p><p><b>Frequency not reported</b>: Arthralgia, arthritis, back pain, cramps, increased creatine phosphokinase, myalgia, myasthenia, myopathy<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Frequency not reported</b>: Dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruritus, sweating, urticaria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Dizziness, headache, hyperkinesia, migraine, paresthesia, seizures, somnolence<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Accidental injury, asthenia, fever, malaise, pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Dyspnea, pharyngitis, rhinitis, sinusitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: QTc prolongation, torsades de pointes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Anorexia, increased alkaline phosphatase, increased LDH, hyperlipidemia, hyperuricemia, hyperglycemia, hypoglycemia, dehydration, redistribution/accumulation of body fat</p><p><b>Postmarketing reports</b>: Metabolic acidosis</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")</p><p></p><p>HIV protease inhibitor therapy:</p><p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, ketoacidosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety, depression, emotional lability, insomnia, sleep disorder, suicidal ideation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reaction</p><p><b>Postmarketing reports</b>: Hypersensitivity reactions (including bronchospasm, moderate to severe rash, fever, edema)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Kidney calculus<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Sexual dysfunction, urine abnormality<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)</p><h3>Ocular</h3><p><b>Frequency not reported</b>: Acute iritis, eye disorder<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA. </p><p id="ref_2">2. AIDSinfo. NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2015 Mar 5]):</p><p id="ref_3">3. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2015 Apr 8]):</p><p id="ref_4">4. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_5">5. Gathe J, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman  S "A randomized phase II study of VIRACEPT, a novel HIV proteas inhibitor, used in combination with stavudine (d4T) vs. stavudin (d4T) alone." Int Conf AIDS 11 (1996): 25(ab.no.mo.b.413)</p><p id="ref_6">6. Damle B,  Hewlett D Jr,  Hsyu PH,  Becker M,  Petersen A "Pharmacokinetics of nelfinavir in subjects with hepatic impairment." J Clin Pharmacol 46 (2006): 1241-9</p><p id="ref_7">7. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8</p><p id="ref_8">8. Aarnoutse RE,  Droste JA,  Van Oosterhout JJ, et al. "Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers." Br J Clin Pharmacol 55 (2003): 115-125</p><p id="ref_9">9. Ghosn J,  Lamotte C,  Ait-Mohand H, et al. "Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients." AIDS 17 (2003): 209-14</p><p id="ref_10">10. Guest JL,  Ruffin C,  Tschampa JM,  DeSilva KE,  Rimland D "Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir." Pharmacotherapy 24 (2004): 727-35</p><p id="ref_11">11. Perry CM,  Frampton JE,  McCormack PL,  Siddiqui MA,  Cvetkovic RS "Nelfinavir: A Review of its Use in the Management of HIV Infection." Drugs 65 (2005): 2209-44</p><p id="ref_12">12. Heeswijk RP,  Khaliq Y,  Gallicano KD, et al. "The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum." Clin Pharmacol Ther 76 (2004): 588-97</p><p id="ref_13">13. Moyle GJ, Youle M, Higgs C, Monaghan J,  Peterkin J, Chapman S, Nelson M "Extended follow-up of safety and activity of agouron's HIV proteinas inhibitor ag1343 (Viracept) in virological responders from the UK phase I/II dose finding study." Int Conf AIDS 11 (1996): 18(ab.no.mo.b.173)</p><p id="ref_14">14. Flanigan TP, Ramratnam B, Graeber C, Hellinger J, Smith D, Wheeler D, Hawley P, Heathchiozzi M, Ward DJ, Brummitt C, Turner J "Prospective trial of paromomycin for cryptosporidiosis in AIDS." Am J Med 100 (1996): 370-2</p><p id="ref_15">15. Hsyu PH,  Schultz-Smith MD,  Lillibridge JH,  Lewis RH,  Kerr BM "Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin." Antimicrob Agents Chemother 45 (2001): 3445-50</p><p id="ref_16">16. Timmermans S,  Tempelman C,  Godfried MH, et al. "Nelfinavir and nevirapine side effects during pregnancy." AIDS 19 (2005): 795-799</p><p id="ref_17">17. Regazzi M,  Maserati R,  Villani P, et al. "Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects." Antimicrob Agents Chemother 49 (2005): 643-9</p><p id="ref_18">18. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_19">19. Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000): s135-42</p><p id="ref_20">20. Gathe JC Jr,  Ive P,  Wood R, et al. "SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients." AIDS 18 (2004): 1529-1537</p><p id="ref_21">21. Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A "Nelfinavir plasma levels under twice-daily and three-times-daily regimens: High interpatient and low intrapatient variability." Ther Drug Monit 23 (2001): 394-8</p><p id="ref_22">22. Puro V,  Soldani F,  De Carli G,  Lazarevic Z,  Mattioli F,  Ippolito G "Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis." AIDS 17 (2003): 1988-90</p><p id="ref_23">23. Abraham PE,  Sorensen SJ,  Baker WH,  Cushing HE "Nelfinavir desensitization." Ann Pharmacother 35 (2001): 553-6</p><p id="ref_24">24. Manfredi R, Calza L, Chiodo F "Gynecomastia associated with highly antiretroviral therapy." Ann Pharmacother 35 (2001): 438-9</p><p id="ref_25">25. Martinez E, Mocroft A, GarciaViejo MA, PerezCuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell "Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study." Lancet 357 (2001): 592-8</p><p id="ref_26">26. Dube MP,  Parker RA,  Tebas P, et al. "Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides." AIDS 19 (2005): 1807-1818</p><p id="ref_27">27. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_28">28. Fantoni M,  Del Borgo C,  Autore C "Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy." AIDS 17 Suppl 1 (2003): S162-9</p><p id="ref_29">29. Fisac C,  Virgili N,  Ferrer E, et al. "A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study." J Clin Endocrinol Metab 88 (2003): 5186-92</p><p id="ref_30">30. Engeler DS,  John H,  Rentsch KM,  Ruef C,  Oertle D,  Suter S "Nelfinavir urinary stones." J Urol 167 (2002): 1384-5</p><p id="ref_31">31. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p><h2>More about nelfinavir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: protease inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nelfinavir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>